Viewing Study NCT07325266


Ignite Creation Date: 2026-03-26 @ 3:15 PM
Ignite Modification Date: 2026-03-26 @ 3:15 PM
Study NCT ID: NCT07325266
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-03-24
First Post: 2026-01-06
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Human Laboratory Study of Apremilast for Alcohol Use Disorder
Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Organization:

Study Overview

Official Title: Human Laboratory Study of Apremilast for Alcohol Use Disorder
Status: NOT_YET_RECRUITING
Status Verified Date: 2026-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Primary: The primary objective of this study is to compare the efficacy of two different maintenance doses of apremilast (tablets) in reducing alcohol craving among subjects with moderate to severe alcohol use disorder (AUD) after two weeks of daily dosing.

Secondary: Secondary objectives include evaluation of two different maintenance doses of apremilast compared with matched placebo on other measures of self-reported alcohol consumption, alcohol craving, alcohol-related negative consequences, AUD symptoms, pain, sleep disturbances, depression, anxiety, quality of life, cigarette smoking, other nicotine use, cannabis use, retention in the study, and safety.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: